×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
THTX – theratechnologies inc. - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
THTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/18
03:28 pm
thtx
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment [Canadian Business Journal (Canada)]
Low
Report
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment [Canadian Business Journal (Canada)]
12/18
01:30 pm
thtx
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Neutral
Report
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
12/10
05:28 pm
thtx
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA [Canadian Business Journal (Canada)]
Neutral
Report
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA [Canadian Business Journal (Canada)]
12/10
03:15 pm
thtx
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
Medium
Report
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
12/9
07:42 am
thtx
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer [Yahoo! Finance]
Medium
Report
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer [Yahoo! Finance]
12/9
07:30 am
thtx
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
Medium
Report
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
12/4
09:28 am
thtx
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada [Canadian Business Journal (Canada)]
Low
Report
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada [Canadian Business Journal (Canada)]
12/4
07:30 am
thtx
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
Neutral
Report
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/19
03:56 pm
thtx
Form 6-K Theratechnologies Inc. For: Dec 19
Low
Report
Form 6-K Theratechnologies Inc. For: Dec 19
12/12
11:59 am
thtx
Form 6-K Theratechnologies Inc. For: Dec 12
Low
Report
Form 6-K Theratechnologies Inc. For: Dec 12
12/11
06:02 am
thtx
Form 6-K Theratechnologies Inc. For: Dec 11
Neutral
Report
Form 6-K Theratechnologies Inc. For: Dec 11
12/9
02:36 pm
thtx
Form 6-K Theratechnologies Inc. For: Dec 09
Low
Report
Form 6-K Theratechnologies Inc. For: Dec 09
12/5
10:44 am
thtx
Form 6-K Theratechnologies Inc. For: Dec 05
Low
Report
Form 6-K Theratechnologies Inc. For: Dec 05
12/4
11:45 am
thtx
Form 6-K Theratechnologies Inc. For: Dec 04
Low
Report
Form 6-K Theratechnologies Inc. For: Dec 04
12/4
08:54 am
thtx
Form 6-K Theratechnologies Inc. For: Dec 03
Medium
Report
Form 6-K Theratechnologies Inc. For: Dec 03
12/2
10:21 am
thtx
Form 6-K Theratechnologies Inc. For: Dec 02
Low
Report
Form 6-K Theratechnologies Inc. For: Dec 02
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/4
Theratechnologies Signs Agreements With Massachusetts General Hospital and Dr. Steven Grinspoon
19.1%
3/3 Theratechnologies Inc. (NASDAQ: THTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $95.50 price target on the stock. 17.7%
4/14 Theratechnologies Announces Financial Results for the First Quarter of 2020 11.8%
10/14 REMINDER - Tesamorelin Study Results on NAFLD Published in Lancet HIV 9.9%
4/16 Theratechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 6.8%
10/21 Theratechnologies Provides Details About R&D Day Webcast 4.7%
3/11 Visceral Fat is a Predictor of Liver Fibrosis and Fibrosis Progression in People Living With HIV 3.8%
3/13 Form 6-K Theratechnologies Inc. For: Mar 13 3.4%
1/10 Theratechnologies Inc. (NASDAQ: THTX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.4%
12/19 Form 6-K Theratechnologies Inc. For: Dec 19 2.6%
3/3 Theratechnologies Inc. (NASDAQ: THTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $95.50 price target on the stock. 17.7%
4/14 Theratechnologies Announces Financial Results for the First Quarter of 2020 11.8%
10/14 REMINDER - Tesamorelin Study Results on NAFLD Published in Lancet HIV 9.9%
4/16 Theratechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 6.8%
10/21 Theratechnologies Provides Details About R&D Day Webcast 4.7%
3/11 Visceral Fat is a Predictor of Liver Fibrosis and Fibrosis Progression in People Living With HIV 3.8%
3/13 Form 6-K Theratechnologies Inc. For: Mar 13 3.4%
1/10 Theratechnologies Inc. (NASDAQ: THTX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.4%
12/19 Form 6-K Theratechnologies Inc. For: Dec 19 2.6%
TOP News Decliners
11/15
Form F-10/A Theratechnologies Inc.
-12.3%
10/10 Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing -7.5%
4/15 Theratechnologies Inc. (THTX) Q1 2020 Earnings Call Transcript [The Motley Fool] -5.4%
12/2 Theratechnologies Inc. (NASDAQ: THTX) is now covered by analysts at Canaccord Genuity. They set a "buy" rating on the stock. -5.1%
11/22 Form EFFECT Theratechnologies Inc. -4.1%
3/31 Form 6-K Theratechnologies Inc. For: Mar 31 -3.6%
11/25 Theratechnologies Starts Commercialization of New EGRIFTA SV?? in the United States -2.6%
10/11 Form F-X Theratechnologies Inc. Filed by: Theratechnologies Inc. -2.0%
2/18 Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2019 -1.8%
3/10 Form 6-K Theratechnologies Inc. For: Mar 10 -1.7%
10/10 Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing -7.5%
4/15 Theratechnologies Inc. (THTX) Q1 2020 Earnings Call Transcript [The Motley Fool] -5.4%
12/2 Theratechnologies Inc. (NASDAQ: THTX) is now covered by analysts at Canaccord Genuity. They set a "buy" rating on the stock. -5.1%
11/22 Form EFFECT Theratechnologies Inc. -4.1%
3/31 Form 6-K Theratechnologies Inc. For: Mar 31 -3.6%
11/25 Theratechnologies Starts Commercialization of New EGRIFTA SV?? in the United States -2.6%
10/11 Form F-X Theratechnologies Inc. Filed by: Theratechnologies Inc. -2.0%
2/18 Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2019 -1.8%
3/10 Form 6-K Theratechnologies Inc. For: Mar 10 -1.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: